Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
225
Views
13
CrossRef citations to date
0
Altmetric
Review

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data

Fumi Varyani1 Queen’s Medical Center, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Konstantinos Argyriou2 Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2026-9678
ORCID Icon,
Frank Phillips1 Queen’s Medical Center, Nottingham University Hospitals NHS Trust, Nottingham, UK
,
Eirini Tsakiridou3 University Hospital of Athens “LAIKO”, Athens, Greece
&
Gordon William Moran2 Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK;4 National Institute of Health Research, Nottingham Biomedical Research Centre at Nottingham University Hospitals National Health Service Trust and the University of Nottingham, Nottingham, UK
Pages 4091-4105 | Published online: 02 Dec 2019

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Daniela Gilardi, Roberto Gabbiadini, Mariangela Allocca, Carmen Correale, Gionata Fiorino, Federica Furfaro, Alessandra Zilli, Laurent Peyrin-Biroulet & Silvio Danese. (2020) PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology & Hepatology 14:9, pages 797-806.
Read now

Articles from other publishers (12)

Anita Afzali, Rina Lukanova, Fritha Hennessy, Sumie Kakehi, Hannah Knight, Gary Milligan & Komal Gupte-Singh. (2023) Unmet Needs in Real-World Advanced Therapy-Naïve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States. Advances in Therapy 40:10, pages 4321-4338.
Crossref
Dawei Huang, Yuexin Zhang, Luyang Kong, Jiajing Lu & Yuling Shi. (2023) Janus kinase inhibitors in autoimmune bullous diseases. Frontiers in Immunology 14.
Crossref
Rajashri R. Naik, Ashok K. Shakya, Safwan M. Aladwan & Mohamed El-Tanani. (2022) Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Frontiers in Pharmacology 13.
Crossref
Chloé Girard, Martha Dirks & Colette Deslandres. (2022) Tofacitinib to Treat Severe Acute Refractory Colitis in a Teenager: Case Report and Review of the Literature. JPGN Reports 3:3, pages e241.
Crossref
Isabel Garrido, Susana Lopes & Guilherme Macedo. (2021) Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 27:12, pages 2010-2022.
Crossref
Liang Wang, Baohui Song, Yan Hu, Jun Chen, Shuaishuai Zhang, Dapeng Chen & Jingyu Wang. (2021) Puerarin Ameliorates 5-Fluorouracil–Induced Intestinal Mucositis in Mice by Inhibiting JAKs. Journal of Pharmacology and Experimental Therapeutics 379:2, pages 147-155.
Crossref
Alessandro Armuzzi & Giuseppina Liguori. (2021) Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Digestive and Liver Disease 53:7, pages 803-808.
Crossref
Rhonda M. Brand, Beverley A. Moore, Ashley Zyhowski, Aaron Siegel, Shikhar Uttam, E. Jeffrey Metter, Jarret Engstrom, Randall E. Brand, Nabanita Biswas, David C. Whitcomb, David G. Binion, Marc Schwartz & Ian McGowan. (2021) Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 320:3, pages G396-G410.
Crossref
María Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodríguez, Manuel Barreiro-de Acosta, Jesús Martínez-Cadilla, María T Arroyo, Noemí Manceñido, Mónica Sierra-Ausín, Isabel Vera-Mendoza, María José Casanova, Pilar Nos, Carlos González-Muñoza, Teresa Martínez, Maia Boscá-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llaó, María Dolores Martín-Arranz, Marta Piqueras, Laura Ramos, Gerard Surís, Fernando Bermejo, Ana Y Carbajo, Diego Casas-Deza, Agnes Fernández-Clotet, María J García, Daniel Ginard, Ana Gutiérrez-Casbas, Luis Hernández, Alfredo J Lucendo, Lucía Márquez, Olga Merino-Ochoa, Francisco J Rancel, Carlos Taxonera, Antonio López Sanromán, Saioa Rubio, Eugeni Domènech & Javier P Gisbert. (2021) Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. Journal of Crohn's and Colitis 15:1, pages 35-42.
Crossref
Hyung-Ook Kim. (2020) Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Archives of Pharmacal Research 43:11, pages 1173-1186.
Crossref
Parvirti Dhillon & Kuljit Singh. (2020) Therapeutic applications of probiotics in ulcerative colitis: An updated review. PharmaNutrition 13, pages 100194.
Crossref
Fernando Magro & Maria Manuela Estevinho. (2020) Is tofacitinib a game‐changing drug for ulcerative colitis?. United European Gastroenterology Journal 8:7, pages 755-763.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.